Cargando…

Management of benign prostatic hyperplasia with silodosin

It has been reported that blockade of α(1A)-adrenoceptor (AR) relieves bladder outlet obstruction, while blockade of α(1D)-AR is believed to alleviate storage symptoms due to detrusor overactivity. Silodosin, (−)-1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2trifluoroethoxy) phenoxy]ethyl}amino)propyl]...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamanishi, Tomonori, Mizuno, Tomoya, Kamai, Takao, Yoshida, Ken-Ichiro, Sakakibara, Ryuji, Uchiyama, Tomoyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2009
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3806400/ https://www.ncbi.nlm.nih.gov/pubmed/24198606

Ejemplares similares

Silodosin in the treatment of benign prostatic hyperplasia
por: Rossi, Maxime, et al.
Publicado: (2010)

Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia
por: Yoshida, Masaki, et al.
Publicado: (2011)

Silodosin for the treatment of clinical benign prostatic hyperplasia: safety, efficacy, and patient acceptability
por: Cho, Hee Ju, et al.
Publicado: (2014)

Extravasation of Urine Associated with Bilateral Complete Ureteral Duplication, Vesicoureteral Reflux and Benign Prostatic Hyperplasia
por: Suzuki, Issei, et al.
Publicado: (2017)

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)

The Effectiveness of Silodosin for Nocturnal Polyuria in Elderly Men With Benign Prostatic Hyperplasia: A Multicenter Study
por: Kim, Young Won, et al.
Publicado: (2015)

Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
por: Sakata, Koichi, et al.
Publicado: (2012)

Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia and Poor Response to Existing Alpha-1 Blockers: The SPLASH Study
por: Takahashi, Hiroshi, et al.
Publicado: (2019)

A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia
por: Manjunatha, R., et al.
Publicado: (2016)

Evaluation of Silodosin and Pelvic Floor Muscle Training in Men with Benign Prostatic Hyperplasia and Overactive Bladder (Silodosing) Study Protocol (Spirit Compliant)
por: Hagovska, Magdalena, et al.
Publicado: (2021)

Effect of silodosin on specific urinary symptoms associated with benign prostatic hyperplasia: analysis of international prostate symptom scores in 2 phase III clinical studies
por: Gittelman, Marc C, et al.
Publicado: (2010)

Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With α(1)-Blockers
por: Kobayashi, Minoru, et al.
Publicado: (2017)

Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study
por: Patil, Siddangouda B., et al.
Publicado: (2017)

Bladder, Bowel, and Sexual Dysfunction in Parkinson's Disease
por: Sakakibara, Ryuji, et al.
Publicado: (2011)

Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study
por: Hagiwara, Kazuhisa, et al.
Publicado: (2016)

Evaluation of static and dynamic Pupillometry changes in men using Silodosin for benign prostatic hypertrophy
por: Karaca, Umut, et al.
Publicado: (2021)

α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
por: Roehrborn, Claus G., et al.
Publicado: (2016)

Increased interferon alpha receptor 2 mRNA levels is associated with renal cell carcinoma metastasis
por: Kamai, Takao, et al.
Publicado: (2007)

The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment of Previously Untreated Japanese Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
por: Tanaka, Yoshinori, et al.
Publicado: (2017)

Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat
por: Shimizu, Shogo, et al.
Publicado: (2015)

Testosterone and benign prostatic hyperplasia
por: Jarvis, Thomas R, et al.
Publicado: (2015)

Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia
por: AbdelRazek, Mostafa, et al.
Publicado: (2022)

Recent advances in managing benign prostatic hyperplasia: The Rezūm System
por: Guelce, Dominique, et al.
Publicado: (2018)

Modern best practice in the management of benign prostatic hyperplasia in the elderly
por: Bortnick, Eric, et al.
Publicado: (2020)

Pathophysiology of clinical benign prostatic hyperplasia
por: Foo, Keong Tatt
Publicado: (2017)

Epidemiology of clinical benign prostatic hyperplasia
por: Lim, Kok Bin
Publicado: (2017)

Botulinum toxin and benign prostatic hyperplasia
por: Ng, Lay Guat
Publicado: (2018)

Benign Prostatic Hyperplasia
Publicado: (2015)

VASTI THERAPY IN THE MANAGEMENT OF BENIGN PROSTATE HYPERPLASIA
por: Gupta, Shivaji, et al.
Publicado: (1997)

Unsolved Issues in Managing Benign Prostatic Hyperplasia
por: Oh, Seung-June
Publicado: (2013)

Focus on Silodosin: Pros and Cons of Uroselectivity
por: Califano, Gianluigi, et al.
Publicado: (2020)

Best practice in the management of benign prostatic hyperplasia in the patients requiring anticoagulation
por: Heiman, Joshua, et al.
Publicado: (2018)

Therapeutic options in the treatment of benign prostatic hyperplasia
por: Sandhu, Jaspreet S
Publicado: (2009)

Recent advances in treatment for Benign Prostatic Hyperplasia
por: van Rij, Simon, et al.
Publicado: (2015)

Metabolic syndrome and benign prostatic hyperplasia: An update
por: Ngai, Ho-Yin, et al.
Publicado: (2017)

Recent advances in prostatectomy for benign prostatic hyperplasia
por: Te, Alexis E.
Publicado: (2019)

Treatment of Benign Prostatic Hyperplasia by Natural Drugs
por: Csikós, Eszter, et al.
Publicado: (2021)

Elevated expression of B7 homolog 4 is associated with disease progression in upper urinary tract urothelial carcinoma
por: Mizuno, Tomoya, et al.
Publicado: (2021)

A 52‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)
por: Yamanishi, Tomonori, et al.
Publicado: (2018)

Update on the management of benign prostatic hyperplasia and the role of minimally invasive procedures
por: Franco, Juan V.A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ngvvqkklupoob1nul3hnvjv74o